Will This New Orphan Drug Go the Distance? (MRK)

Will This New Orphan Drug Go the Distance?

Endocyte (Nasdaq: ECYT ) has partnered with pharma powerhouse Merck (NYSE: MRK ) to develop its experimental drug vintafolide, a compound with orphan drug status in Europe that's used to treat a specific type of ovarian cancer. The companies submitted their official application for the approval of vintafolide to the European Medicines Agency (EMA) today.

As this drug goes under review, health-care analysts Max Macaluso and Brenton Flynn discuss the details of this partnership and another cancer drug for which Merck is seeking approval along with biotech Ariad (Nasdaq: ARIA ) .

For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand-new premium research report today. Our senior biotech analyst, Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.